HRMY Stock Price, Harmony Biosciences Holdings, . Quote, Chart

Market Summary

USD30.20+0.06

Market Closed

0.20%

HRMY Alerts

Big jump in Revenue (Y/Y)

HRMY Stock Price

View Fullscreen

HRMY RSI Chart

HRMY Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

12.46

Price/Sales (Trailing)

2.78

EV/EBITDA

7.4

Price/Free Cashflow

8.26

HRMY Price/Sales (Trailing)

HRMY Profitability

EBT Margin

30.35%

Return on Equity

26.72%

Return on Assets

16.26%

Free Cashflow Yield

12.11%

HRMY Fundamentals

HRMY Revenue

Revenue (TTM)

617.5M

Rev. Growth (Yr)

29.79%

Rev. Growth (Qtr)

-8.19%

HRMY Earnings

Earnings (TTM)

137.7M

Earnings Growth (Yr)

30.01%

Earnings Growth (Qtr)

44.07%

Breaking Down HRMY Revenue

Last 7 days

-2.3%

Last 30 days

2.4%

Last 90 days

-8.1%

Trailing 12 Months

-16.4%

How does HRMY drawdown profile look like?

HRMY Financial Health

Current Ratio

3.11

Debt/Equity

0.34

Debt/Cashflow

1.19

HRMY Investor Care

Buy Backs (1Y)

5.28%

Diluted EPS (TTM)

2.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	617.5M	0	0	0
2023	471.7M	498.9M	541.9M	582.0M
2022	331.1M	364.3M	400.8M	437.9M
2021	199.6M	235.4M	270.5M	305.4M
2020	44.4M	82.9M	121.3M	159.7M
2019	0	0	0	6.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Harmony Biosciences Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	kapadia sandip	acquired	-	-	15,000	chief financial officer
Mar 29, 2024	kapadia sandip	sold (taxes)	-269,077	33.58	-8,013	chief financial officer
Mar 15, 2024	dierks jeffrey	sold	-383,328	32.00	-11,979	chief commercial officer
Mar 15, 2024	dierks jeffrey	acquired	98,467	8.22	11,979	chief commercial officer
Mar 08, 2024	dierks jeffrey	sold	-6,208	32.00	-194	chief commercial officer
Mar 08, 2024	dierks jeffrey	acquired	1,594	8.22	194	chief commercial officer
Mar 29, 2023	kapadia sandip	sold (taxes)	-514,211	33.36	-15,414	chief financial officer
Mar 29, 2023	kapadia sandip	acquired	-	-	30,000	chief financial officer
Dec 14, 2022	nielsen jack	sold	-169,927	59.96	-2,834	-
Dec 14, 2022	wicki andreas	sold	-7,800	60.00	-130	-

Which funds bought or sold HRMY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CIBC Private Wealth Group, LLC	new	-	46,808	46,808	-%
May 10, 2024	CORNERCAP INVESTMENT COUNSEL INC	unchanged	-	22,419	588,154	0.09%
May 10, 2024	VANGUARD GROUP INC	reduced	-1.27	3,140,920	121,836,000	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-65.14	-2,531,260	1,438,530	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	8.19	62,357	562,297	-%
May 10, 2024	CREDIT SUISSE AG/	unchanged	-	49,176	1,290,080	-%
May 10, 2024	BlackRock Inc.	reduced	-1.34	4,978,850	198,886,000	-%
May 10, 2024	Vontobel Holding Ltd.	reduced	-33.96	-107,320	235,060	-%
May 10, 2024	Hillsdale Investment Management Inc.	added	8.92	273,198	2,337,170	0.18%
May 10, 2024	OSAIC HOLDINGS, INC.	sold off	-100	-15,890	-	-%

Are Funds Buying or Selling HRMY?

Are funds buying HRMY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HRMY

No. of Funds

HRMY Alerts

Big jump in Revenue (Y/Y)

Unveiling Harmony Biosciences Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	valor iv pharma holdings, llc	19.2%	11,218,033	SC 13G/A
Feb 13, 2024	vanguard group inc	6.27%	3,674,764	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 24, 2024	blackrock inc.	10.2%	6,002,374	SC 13G/A
Oct 06, 2023	blackrock inc.	10.2%	6,131,534	SC 13G/A
Feb 14, 2023	vivo capital viii, llc	4.3%	2,571,024	SC 13G/A
Feb 14, 2023	hbm healthcare investments (cayman) ltd.	3.6%	2,147,943	SC 13G/A
Feb 13, 2023	valor iv pharma holdings, llc	18.9%	11,218,033	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.49%	3,254,641	SC 13G

Recent SEC filings of Harmony Biosciences Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
May 03, 2024	4	Insider Trading
May 03, 2024	8-K	Current Report
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 11, 2024	8-K	Current Report
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to Harmony Biosciences Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Harmony Biosciences Holdings, Inc. News

Latest updates

Harmony Biosciences Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-8.2%	155	168	160	134	119	128	117	107	85.00	91.00	81.00	74.00	60.00	56.00	46.00	38.00	20.00	-
Gross Profit	1.5%	127	125	128	109	98.00	101	94.00	88.00	71.00	73.00	66.00	61.00	49.00	46.00	38.00	32.00	16.00	-
Operating Expenses	-11.7%	75.00	85.00	63.00	62.00	58.00	54.00	82.00	55.00	43.00	45.00	45.00	38.00	35.00	38.00	27.00	24.00	26.00	-
S&GA Expenses	1.3%	27.00	27.00	23.00	25.00	23.00	21.00	20.00	20.00	18.00	19.00	16.00	17.00	16.00	18.00	13.00	12.00	13.00	-
R&D Expenses	-26.8%	22.00	30.00	17.00	15.00	13.00	10.00	41.00	13.00	8.00	7.00	12.00	6.00	5.00	8.00	4.00	4.00	3.00	-
EBITDA Margin	0.4%	0.34*	0.34*	0.37*	0.31*	0.30*	0.28*	0.26*	0.24*	0.23*	0.20*	0.13*	0.22*	-	-	-	-	-	-
Interest Expenses	-44.0%	5.00	8.00	5.00	5.00	6.00	7.00	4.00	4.00	4.00	8.00	3.00	7.00	7.00	7.00	7.00	6.00	6.00	-
Income Taxes	2.8%	13.00	13.00	13.00	10.00	8.00	-4.41	-79.98	6.00	2.00	-	-0.90	2.00	-	-	-	-	-	-
Earnings Before Taxes	30.5%	52.00	40.00	52.00	44.00	38.00	44.00	8.00	29.00	23.00	24.00	-10.52	16.00	7.00	-0.21	2.00	-0.03	-38.62	-
EBT Margin	1.9%	0.30*	0.30*	0.33*	0.27*	0.25*	0.24*	0.21*	0.18*	0.16*	0.12*	0.05*	0.11*	-	-	-	-	-	-
Net Income	44.1%	38.00	27.00	38.00	34.00	29.00	49.00	88.00	24.00	21.00	23.00	-9.62	14.00	7.00	-0.21	2.00	-0.03	-38.62	-
Net Income Margin	0.7%	0.22*	0.22*	0.28*	0.40*	0.40*	0.41*	0.39*	0.16*	0.15*	0.11*	0.04*	0.10*	-	-	-	-	-	-
Free Cashflow	-59.3%	31.00	77.00	63.00	37.00	43.00	27.00	55.00	34.00	29.00	38.00	30.00	18.00	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	4.4%	847	811	778	760	715	674	643	505	464	433	391	360	337	427	320	107
Current Assets	6.3%	480	451	463	456	418	400	382	323	280	284	241	205	178	263	250	31.00
Cash Equivalents	6.8%	333	312	325	317	289	245	262	237	225	235	190	160	142	229	222	25.00
Inventory	9.2%	6.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	5.00	4.00	5.00	5.00	4.00	4.00	2.00	1.00
Net PPE	-42.6%	0.00	0.00	0.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-3.7%	332	344	296	275	272	271	300	259	250	247	239	233	229	330	226	118
Current Liabilities	-5.8%	154	164	112	93.00	85.00	79.00	107	66.00	57.00	54.00	48.00	37.00	33.00	135	32.00	20.00
Long Term Debt	-2.0%	175	179	182	180	185	190	190	190	190	190	190	196	195	194	193	98.00
LT Debt, Current	0%	15.00	15.00	15.00	11.00	7.00	2.00	2.00	2.00	2.00	2.00	2.00	-	-	-	-	-
LT Debt, Non Current	-2.0%	175	179	182	180	185	190	190	190	190	190	190	196	195	194	193	98.00
Shareholder's Equity	10.4%	515	467	481	485	443	403	344	247	215	187	152	127	108	97.00	95.00	-
Retained Earnings	26.8%	-104	-143	-169	-208	-242	-272	-320	-408	-432	-453	-476	-466	-480	-488	-487	-422
Additional Paid-In Capital	1.7%	621	610	652	694	686	675	665	655	647	640	628	593	589	585	583	-
Shares Outstanding	0.0%	57.00	57.00	59.00	60.00	60.00	60.00	59.00	59.00	59.00	58.00	57.00	57.00	-	-	-	-
Float	-	-	-	-	1,175	-	-	-	1,360	-	-	-	731	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-59.4%	31,141	76,665	63,100	37,063	42,559	26,678	55,205	33,731	28,852	37,533	30,424	18,070	12,530	10,047	8,838	4,832	-26,702	-	-
Share Based Compensation	17.3%	10,394	8,863	7,991	7,648	7,203	7,260	7,007	7,278	4,628	4,198	4,253	3,907	3,301	2,823	1,073	429	368	-	-
Cashflow From Investing	82.8%	-6,186	-36,065	-813	-7,771	-1,790	-46,895	-32,445	-22,447	-40,045	-	-93.00	-201	-100,004	-2,000	-	-	-	-	-
Cashflow From Financing	93.2%	-3,634	-53,523	-55,099	-339	3,409	2,658	2,050	750	1,383	7,072	-313	648	12.00	-1,156	136,622	-67.00	73,762	-	-
Buy Backs	-100.0%	-	50,000	50,543	-	-	-	-	-	-	-	-	-	-	-	-	167	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HRMY Income Statement

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
Net product revenue	$ 154,615	$ 119,126
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Cost of product sold	$ 27,484	$ 20,780
Cost, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Gross profit	$ 127,131	$ 98,346
Operating expenses:
Research and development	22,189	13,289
Sales and marketing	27,233	22,572
General and administrative	25,676	22,062
Total operating expenses	75,098	57,923
Operating income	52,033	40,423
Other (expense) income, net	(141)	2
Interest expense	(4,535)	(5,731)
Interest income	4,428	3,086
Income before income taxes	51,785	37,780
Income tax expense	(13,451)	(8,295)
Net income	38,334	29,485
Unrealized (loss) income on investments	(173)	120
Comprehensive income	$ 38,161	$ 29,605
EARNINGS PER SHARE:
Basic	$ 0.68	$ 0.49
Diluted	$ 0.67	$ 0.48
Weighted average number of shares of common stock - basic	56,771,251	59,732,157
Weighted average number of shares of common stock - diluted	57,597,627	61,221,511

HRMY Balance Sheet

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 332,981	$ 311,660
Investments, short-term	39,369	41,800
Trade receivables, net	79,719	74,140
Inventory, net	5,857	5,363
Prepaid expenses	12,894	12,570
Other current assets	8,683	5,537
Total current assets	479,503	451,070
NONCURRENT ASSETS:
Property and equipment, net	213	371
Restricted cash	270	270
Investments, long-term	81,244	72,169
Intangible assets, net	131,147	137,108
Deferred tax asset	147,639	144,162
Other noncurrent assets	6,969	6,298
Total noncurrent assets	367,482	360,378
TOTAL ASSETS	846,985	811,448
CURRENT LIABILITIES:
Trade payables	15,144	17,730
Accrued compensation	7,317	23,747
Accrued expenses	91,699	99,494
Current portion of long-term debt	15,000	15,000
Other current liabilities	25,093	7,810
Total current liabilities	154,253	163,781
NONCURRENT LIABILITIES:
Long-term debt, net	174,996	178,566
Other noncurrent liabilities	2,342	2,109
Total noncurrent liabilities	177,338	180,675
TOTAL LIABILITIES	331,591	344,456
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS' EQUITY:
Common stock-$0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 56,791,214 and 56,769,081 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid in capital	620,507	610,266
Accumulated other comprehensive (loss) income	(171)	2
Accumulated deficit	(104,943)	(143,277)
TOTAL STOCKHOLDERS' EQUITY	515,394	466,992
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 846,985	$ 811,448

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

CEO	Dr. Jeffrey M. Dayno M.D.
WEBSITE	harmonybiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	200

Harmony Biosciences Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Harmony Biosciences Holdings, Inc.? What does HRMY stand for in stocks?

HRMY is the stock ticker symbol of Harmony Biosciences Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harmony Biosciences Holdings, Inc. (HRMY)?

As of Mon May 13 2024, market cap of Harmony Biosciences Holdings, Inc. is 1.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HRMY stock?

You can check HRMY's fair value in chart for subscribers.

What is the fair value of HRMY stock?

You can check HRMY's fair value in chart for subscribers. The fair value of Harmony Biosciences Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Harmony Biosciences Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HRMY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Harmony Biosciences Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether HRMY is over valued or under valued. Whether Harmony Biosciences Holdings, Inc. is cheap or expensive depends on the assumptions which impact Harmony Biosciences Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HRMY.

What is Harmony Biosciences Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, HRMY's PE ratio (Price to Earnings) is 12.46 and Price to Sales (PS) ratio is 2.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HRMY PE ratio will change depending on the future growth rate expectations of investors.